Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Resistance against reverse transcriptase inhibitors.

W A O'Brien1

  • 1Departments of Medicine, Pathology, and Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555-0835, USA. wobrien@utmb.edu.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|June 22, 2000
PubMed
Summary

Drug resistance limits antiretroviral therapy effectiveness in human immunodeficiency virus (HIV)-infected patients. New mutation complexes can cause broad cross-resistance, necessitating improved resistance assays for clinical use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recent developments in hospital organization and medical practice that may affect the future.

Journal. Iowa State Medical Society·2010
Same author

Public health cancer control.

The Journal-lancet·2010
Same author

The practice of general medicine.

The Diplomate·2010
Same author

Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults.

Vaccine·2001
Same author

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.

Journal of virology·2001
Same author

Resistance to apoptosis in HIV-infected CD4+ T lymphocytes is mediated by macrophages: role for Nef and immune activation in viral persistence.

Journal of immunology (Baltimore, Md. : 1950)·2000

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • Antiretroviral therapy (ART) response in HIV-infected patients is often limited by the development of drug resistance.
  • HIV's high mutation and replication rates, coupled with selective drug pressure, drive the emergence of resistance.
  • Highly Active Antiretroviral Therapy (HAART), using multiple drugs, achieves durable viral suppression but is challenged by resistance.

Purpose of the Study:

  • To review the mechanisms of drug resistance in HIV.
  • To discuss the impact of combination therapy on viral load reduction.
  • To highlight the challenges and future directions for HIV drug resistance assays.

Main Methods:

  • Review of existing literature on HIV drug resistance.
  • Analysis of the impact of nucleoside reverse transcriptase inhibitors (RTIs) and other ART components.

Related Experiment Videos

  • Discussion of genotypic and phenotypic resistance assay development.

    • Main Results:

    • Emergence of drug resistance is a primary limitation to effective ART in HIV.
    • HAART, particularly with multiple RTIs, leads to significant viral load reduction and suppression.
    • Specific amino acid changes confer resistance to RTIs, with new mutation complexes causing broad cross-resistance.

    Conclusions:

    • Durable viral suppression with ART is achievable but threatened by emerging drug resistance.
    • Further development and refinement of genotypic and phenotypic resistance assays are crucial for widespread clinical application.
    • Understanding resistance mechanisms is key to optimizing HIV treatment strategies.